Catalent Pharma Solutions

Catalent Pharma Solutions has appointed Scott Neilson as vice president of Operations Development, Elaine Dymond as vice president of Quality, Ronald Overhiser as vice president of Innovation Operations, and Evjatar Cohen as vice president of Portfolio Management.

Mr. Neilson will be responsible for leading and executing Catalent’s growth and investment plan for its Blow-Fill-Seal business at the company’s sterile facility in Woodstock, IL.He joins the company with more than 25 years of multi-functional, global experience in all phases of the drug development and manufacturing cycle. Most recently, he was chief operating officer at AAI Pharma, Inc. Mr. Neilson also held senior level leadership roles at MDS Pharma Services, Laboratory Corp. of America, Covance, and SmithKline Beecham.

Ms. Dymond will be responsible for quality and regulatory leadership for Catalent’s softgel and modified release technologies in Europe, Japan and Australia. Ms. Dymond has more than 20 years of experience with GMP, having held technical roles within Quality, Compliance, Validation and Quality Control in sterile, biological and solid dosage forms. She has worked at the UK National Health Service, The Wellcome Foundation/Glaxo Wellcome, GlaxoSmithKline, Sanofi-Aventis, and most recently at Merck/Schering-Plough as the head of Quality, UK. She will be based in Catalent’s Swindon, UK facility.

Mr. Overhiser will drive Catalent’s global operations for innovation. He has 20 years of experience in healthcare including leadership roles across both R&D and commercial organizations. Most recently, Mr. Overhiser led R&D Operations for GE Healthcare Medical Diagnostics, where he was responsible for driving operational rigor and efficiency across the R&D organization. Mr. Overhiser will be based in Somerset, NJ.

Mr.Cohen will manage Catalent’s Innovation portfolio to help ensure the product and technology pipeline is balanced and driving growth. Mr. Cohen has 15 years of pharmaceutical experience having held positions in project management, Quality Assurance, and R&D. Most recently, he was director of legal affairs at Teva Pharmaceuticals, where he implemented project and portfolio management best practices, including an IP risk assessment for an R&D pipeline of more than 1,000 products. Mr. Cohen will be based in Somerset, NJ.

Click here to learn more about Catalent